Navigating the Use of Targeted Therapies and Individualizing Care for Patients With Ulcerative Colitis

This activity includes patient counseling vignettes.

This activity was originally broadcast live at PTCE and Asembia Specialty Pharmacy Day of Education 2023.

Program Description
Ulcerative colitis (UC) is a chronic immune-mediated inflammatory disease affecting the large intestine, rectum, and colon that can significantly impact patients’ quality of life. There continues to be unmet needs and challenges with treatment options that have conventionally been used. Several options, such as the sphingosine-1 phosphate receptor modulators, have emerged to treat UC over the last few years, positively altering the treatment paradigm for patients. A multidisciplinary approach is necessary to ensure improved clinical outcomes and effectiveness of selected treatment and reduction of associated burdens. Through this program, specialty pharmacists will increase their knowledge of the new and emerging treatment options and be able to provide proper and pertinent education to their patients. This activity will enable pharmacists to help guide the selection of appropriate medications for patients with UC based on factors such as mechanisms of action, patient comorbidities, adverse effect management, and administration, improving patients’ overall quality of life through individualized care.

Target Audience: Specialty Pharmacist

Type of Activity: Application
Release date: October 17, 2023
Expiration date: October 17, 2024

Learner level: Foundational and intermediate

Time to complete activity: 1.5 hours
Fee: Free

Educational Objectives

At the completion of this activity, participants will be able to:

• Examine challenges impacting the diagnosis and treatment that contribute to disease burden of ulcerative colitis (UC) as well as limitations of conventional therapy
• Analyze the emerging place in therapy of sphingosine 1 phosphate (S1P) receptor modulators for management of UC, including mechanism of action and safety and efficacy data
• Apply counseling strategies to individualize the management of UC with oral therapies including S1P receptor modulators to improve patient adherence and treatment outcomes

Pharmacy Times Continuing Education^™ is accredited by the Accreditation Council for Pharmacy Education (ACPE) as a provider of continuing pharmacy education. This activity is approved for 1.5 contact hours (0.15 CEU) under the ACPE universal activity number 0290-0000-23-399-H01-P. The activity is available for CE credit through October 17, 2024.

Instructions for Completing the Activity and Receiving CPE Credit

To receive CPE credit, participants must complete the pretest, view the activity in its entirety, complete the posttest, and complete the online activity evaluation. After successful completion of the online activity evaluation, you can submit your credit to CPE Monitor. You may view your credit within 48 hours at www.mycpemonitor.net. All participants must request credit before the activity expiration date. CE credit will not be issued after this date.

Disclosures

The following contributors have no relevant financial relationships with commercial interests to disclose:

Pharmacy Times Continuing Education^™ Planning Staff—Jim Palatine, RPh, MBA; Maryjo Dixon, RPh, MBA; Rose Namissa-Buszka, PharmD, BCPS, CHCP; Kylie Ferrentino; Susan Pordon; Brianna Winters; Chloe Taccetta; and Rebecca Green have no relevant financial relationships with commercial interests to disclose.

Faculty

David Choi, PharmD, BCACP, has the following relevant financial relationships with commercial interests to disclose:

Consultant: Bristol Myers Squibb, Boehringer Ingelheim, AbbVie, Janssen Pharmaceuticals

Speaker's Bureau: Janssen Pharmaceuticals

Anonymous peer reviewers were used as part of content validation and conflict resolution. The peer reviewers have no relevant financial relationships with commercial interests to disclose.

Educational Disclaimer
CPE activities are offered solely for educational purposes and do not constitute any form of professional advice or referral. Discussions concerning drugs, dosages, and procedures may reflect the clinical experience of the author(s) or they may be derived from the professional literature or other sources and may suggest uses that are investigational in nature and not approved labeling or indications. Participants are encouraged to refer to primary references or full prescribing information resources.

For questions about this internet CPE activity, please contact:
[email protected]
Privacy Policy and Terms of Use Information:
www.pharmacytimes.org/terms